Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APB-A101
- Development stage
- Preclinical
- Lead developer
- APITBIO
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
APB-A101 is a monoclonal antibody being developed by APITBIO for the treatment of Hepatitis B Virus (HBV) infection. It specifically targets the preS1 region of the HBV large surface protein. The preS1 region is critical for the virus's attachment to the sodium taurocholate cotransporting polypeptide (NTCP) receptor on hepatocytes. By binding to preS1, APB-A101 is designed to neutralize the virus and block its entry into liver cells, potentially reducing viral load and preventing the spread of infection. It is currently in the preclinical stage of development, specifically in the discovery and cell line development phase.
02
Targets
preS1 (HBV presurface protein 1)
Beyond the preview
Go deeper on APB-A101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APB-A101.